EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An ORFV F1L mRNA Vaccine Candidate: Preparation, Immunogenicity, and Comparison with a Commercial Live Vaccine

Yusheng Lin iD, Jinxiu Jiang, Weiwei Liu, Kul Raj Rai iD, Yongliang Che

Animals · 22.07.2026 · 16 (14) · 2274

DOI: 10.3390/ani16142274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animals, online erschienen am 22.07.2026. Verfasst von Yusheng Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Animal Husbandry & Veterinary Medicine, Fujian Academy of Agricultural Sciences, Fuzhou 350013, China. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Public welfare Project, Natural Science Foundation of Fujian Province, Fujian Province Agricultural High-quality Development beyond “5511” Collaborative Innovation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Orf virus (ORFV) is a major pathogen in goats and sheep, and control currently depends mainly on commercial live vaccines. Although mRNA vaccines have revolutionized human medicine, their use in veterinary settings is largely unexplored. In this study, an mRNA vaccine candidate encoding the ORFV F1L protein (F1L-mRNA-LNP) was developed via in vitro transcription and encapsulated in lipid nanoparticles. BALB/c mice were divided into five groups (n = 14 each): three receiving different doses of F1L-mRNA-LNP (5, 10, or 15 μg), one receiving a commercial live vaccine (CV), and a PBS control group. Mice were immunized intramuscularly and boosted after 14 days; immune responses were assessed 14 days later following ARRIVE 2.0 guidelines. Both the F1L-mRNA-LNP and CV vaccines induced specific antibodies versus PBS (p < 0.01). The 10 μg mRNA group showed Th1 cytokine and CD8+ T cell responses comparable to CV (p > 0.05), whereas IL-4 (Th2) was significantly higher in the CV group (p < 0.05). Neutralizing antibody titers did not differ between groups, indicating that the mRNA vaccine induces comparable Th1 cellular immunity but weaker Th2 humoral immunity. Upon ORFV challenge, the 10 μg F1L-mRNA-LNP vaccine protected BALB/c mice, as evidenced by stable body weight, no clinical symptoms, and reduced viral load, with efficacy comparable to CV (p > 0.05). This study provides strong evidence supporting the optimization of ORFV mRNA vaccines and highlights the translational potential of the F1L-mRNA-LNP candidate vaccine for veterinary applications.

Schlagwörter

Stichwörter der Autor:innen

Orf viruscommercial vaccineimmunogenicitylipid nanoparticlesmRNA vaccine

Autor:innen und Institutionen

  • Institute of Animal Husbandry & Veterinary Medicine, Fujian Academy of Agricultural Sciences, Fuzhou 350013, China.
  • NAST Biomedical Research Laboratory, Faculty of Science, Nepal Academy of Science and Technology (NAST), GPO Box:3323, Khumaltar, Lalitpur 44700, Nepal.

ORCID-Profile: Yusheng Lin, Kul Raj Rai

Förderung

  • Fujian Public welfare Project
  • Natural Science Foundation of Fujian Province
  • Fujian Province Agricultural High-quality Development beyond “5511” Collaborative Innovation Project
  • Special Frontier Exploration Program of the Collaborative Innovation Engineering Project

Zitieren

APA

Lin, Y., Jiang, J., Liu, W., Rai, K. R., & Che, Y. (2026). An ORFV F1L mRNA Vaccine Candidate: Preparation, Immunogenicity, and Comparison with a Commercial Live Vaccine. Animals, 16(14), 2274. https://doi.org/10.3390/ani16142274

Vancouver

Lin Y, Jiang J, Liu W, Rai KR, Che Y. An ORFV F1L mRNA Vaccine Candidate: Preparation, Immunogenicity, and Comparison with a Commercial Live Vaccine. Animals. 2026;16(14):2274. doi:10.3390/ani16142274

BibTeX
@article{Lin2026,
  author = {Lin, Yusheng and Jiang, Jinxiu and Liu, Weiwei and Rai, Kul Raj and Che, Yongliang},
  title = {An ORFV F1L mRNA Vaccine Candidate: Preparation, Immunogenicity, and Comparison with a Commercial Live Vaccine},
  journal = {Animals},
  year = {2026},
  volume = {16},
  number = {14},
  pages = {2274},
  doi = {10.3390/ani16142274}
}
Kostenlos starten →